Pacing-induced left ventricular dysfunction: detection and reversal
Permanent cardiac pacing prevents bradycardia, supports atrioventricular conduction, and can be lifesaving in patients with conduction disease. Yet a high proportion of right ventricular pacing may activate the ventricles in an abnormal sequence. Over time, this electrical dyssynchrony can produce adverse remodeling, reduced left ventricular ejection fraction (LVEF), functional mitral regurgitation, and symptoms of heart failure.
This condition is often called pacing-induced cardiomyopathy (PICM), although definitions vary. Some studies use an absolute fall in LVEF, while others emphasize a decline from baseline accompanied by heart failure symptoms or ventricular dilation. The lack of a single diagnostic threshold makes systematic surveillance particularly important.
The central clinical challenge is distinguishing a pacing-related decline from ischemic heart disease, uncontrolled hypertension, valvular disease, tachyarrhythmia, infiltrative disease, or progression of an underlying cardiomyopathy. Early recognition creates an opportunity to modify the pacing strategy before ventricular dysfunction becomes advanced or irreversible.
How ventricular pacing changes cardiac mechanics
Conventional right ventricular apical pacing can resemble left bundle branch block activation. The impulse travels through myocardium rather than the His–Purkinje system, producing a wide paced QRS and delayed activation of selected left ventricular segments. Septal and lateral wall contraction become less coordinated, reducing mechanical efficiency and increasing wall stress.
The physiological effect depends on pacing site, ventricular pacing burden, intrinsic conduction, QRS duration, myocardial substrate, and atrioventricular timing. A patient with a narrow native QRS and normal LVEF may tolerate a moderate burden for years, whereas a patient with prior infarction or pre-existing conduction delay may deteriorate sooner.
Pacing-induced left ventricular dysfunction is usually a gradual process, but symptoms can emerge abruptly when reduced contractile reserve combines with atrial fibrillation, renal fluid shifts, ischemia, or poorly controlled blood pressure. In patients receiving hemodialysis, volume variation and arrhythmia management can obscure the source of worsening dyspnea; guidance on atrial fibrillation in dialysis offers useful context for this complex overlap.
Identifying patients at higher risk
A high right ventricular pacing percentage is the most practical warning signal. Risk rises substantially when ventricular pacing is frequent, although no single percentage applies equally to every patient. Device interrogation should review cumulative pacing, trends over time, atrial rhythm, mode switches, programmed atrioventricular intervals, and episodes of nonsustained or sustained ventricular arrhythmia.
Baseline characteristics also matter. Older age, male sex, pre-existing LVEF impairment, coronary artery disease, prior myocardial infarction, chronic kidney disease, atrial fibrillation, prolonged native or paced QRS duration, and significant ventricular dyssynchrony have all been associated with a higher likelihood of decline. A patient with a high pacing burden and a low-normal baseline LVEF deserves closer follow-up than someone with robust ventricular function and intact intrinsic conduction.
Risk assessment should begin before implantation. If substantial ventricular pacing is expected, the implanting team should consider whether conventional right ventricular pacing is appropriate or whether conduction-system pacing or cardiac resynchronization therapy (CRT) may provide a better long-term physiological profile. The choice must reflect anatomy, operator expertise, procedural risk, life expectancy, and the likelihood that the patient will require near-continuous pacing.
Detecting decline before heart failure becomes advanced
Clinical review remains essential. Exertional breathlessness, reduced exercise tolerance, orthopnea, edema, unexplained fatigue, declining blood pressure tolerance, and recurrent admissions may indicate deteriorating ventricular performance. Symptoms should be interpreted alongside weight trends, renal function, blood pressure, rhythm status, and medication adherence rather than attributed automatically to pacing.
Echocardiography is the principal surveillance tool. LVEF should be compared with a reliable pre-implant study, ideally using the same imaging method and consistent measurement approach. Left ventricular end-diastolic volume, global longitudinal strain, mechanical dyssynchrony, left atrial size, right ventricular function, and functional mitral regurgitation can provide additional information. A fall in strain may precede a measurable reduction in LVEF, although strain values vary across vendors and laboratories.
Device interrogation and electrocardiography complete the assessment. A paced QRS width, pacing percentage, atrial fibrillation burden, and evidence of loss of atrioventricular synchrony can reveal a modifiable driver. If the clinical picture is disproportionate to pacing findings, evaluate for coronary ischemia, tachycardia-mediated cardiomyopathy, myocarditis, infiltrative disease, uncontrolled hypertension, and primary valve disease.
| Finding | Why it matters | Practical response |
|---|---|---|
| High right ventricular pacing burden | Indicates sustained exposure to electrical dyssynchrony | Review programming, intrinsic conduction, and upgrade options |
| Widened paced QRS | Suggests inefficient ventricular activation | Consider conduction-system pacing or CRT in the appropriate patient |
| Falling LVEF or worsening strain | Signals adverse remodeling | Repeat imaging, investigate competing causes, and discuss device revision |
| New atrial fibrillation or high atrial arrhythmia burden | Can worsen filling and increase heart failure risk | Optimize rhythm or rate management and restore synchrony when feasible |
| New mitral regurgitation or ventricular dilation | Reflects mechanical consequences of dyssynchrony | Treat congestion and assess whether resynchronization could reverse remodeling |
Reversing dysfunction with resynchronization
When pacing-related dysfunction is suspected, the first step is to confirm that the decline is clinically meaningful and that other causes have been considered. Guideline-directed medical therapy for heart failure with reduced ejection fraction should be initiated or optimized when tolerated. This may include an angiotensin receptor–neprilysin inhibitor or another renin–angiotensin system blocker, an evidence-based beta blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-2 inhibitor.
Programming changes may reduce unnecessary right ventricular pacing in patients who retain reliable intrinsic atrioventricular conduction. Longer atrioventricular delays, managed ventricular pacing algorithms, and appropriate mode selection can help, but they are not suitable for patients with advanced atrioventricular block or those who become symptomatic because of excessively long delays. Programming should be verified with surface electrocardiography rather than assumed from the device report.
For established dysfunction with a high pacing burden, upgrading to CRT is a well-established strategy in selected patients. Biventricular pacing can improve electrical synchrony, LVEF, functional capacity, ventricular volumes, and heart failure symptoms. Response is not universal; scar burden, lead position, venous anatomy, renal status, atrial rhythm, and the accuracy of left ventricular lead placement all influence outcomes.
Conduction-system pacing, including His-bundle pacing and left bundle branch area pacing, seeks to activate the ventricles through the native conduction network. It may narrow the QRS and restore more physiological contraction without a coronary sinus lead. Lead placement can be technically demanding, and long-term comparative evidence continues to evolve. In patients with complex ventricular arrhythmias or failed transvenous options, principles from epicardial ablation techniques may also be relevant to broader procedural planning, although ablation itself does not correct pacing dyssynchrony.
Choosing and managing the replacement strategy
Device revision should be individualized. CRT may be favored when LVEF is substantially reduced, heart failure symptoms are persistent, or a high percentage of ventricular pacing is unavoidable. Conduction-system pacing can be attractive when preserving physiological activation is a priority or when coronary sinus anatomy limits CRT. Both approaches require careful attention to venous access, infection risk, lead extraction issues, anticoagulation, and future generator procedures.
Leadless pacemakers avoid a subcutaneous pocket and transvenous lead, which can be advantageous in patients with recurrent pocket infection, limited venous access, or selected dialysis-related vascular concerns. However, traditional single-chamber leadless systems generally cannot provide the same atrioventricular and resynchronization functions as a multi-lead system. Experience with leadless pacemaker performance should therefore be considered alongside the patient’s pacing indication and risk of ventricular dysfunction.
A device upgrade is not simply a hardware procedure. Patients need counseling about expected benefits, possible nonresponse, infection, lead complications, phrenic nerve stimulation, contrast exposure, and the need for continued heart failure treatment. A multidisciplinary team involving electrophysiology, heart failure specialists, imaging experts, and, when necessary, cardiac surgery can improve decision-making in complex cases.
Following recovery and preventing recurrence
Reverse remodeling may begin within months after resynchronization or a successful change in activation pattern, but the pace varies. Clinical status, LVEF, ventricular volumes, strain, QRS duration, mitral regurgitation, renal function, and arrhythmia burden should be reassessed after the device has stabilized and medical therapy has been titrated. A lack of early symptomatic improvement does not always indicate treatment failure, particularly when severe structural disease or competing illness is present.
Persistent dysfunction requires a structured review. Confirm effective biventricular or conduction-system capture, exclude frequent premature ventricular contractions, assess atrial fibrillation and loss of atrioventricular synchrony, and verify left ventricular lead position or conduction-system thresholds. Ischemia, scar, uncontrolled hypertension, medication intolerance, and inadequate heart failure therapy should be revisited rather than overlooked.
Practical monitoring priorities include:
- Record baseline LVEF, ventricular volumes, strain when available, native QRS, and anticipated pacing burden before implantation.
- Interrogate the device after implantation and at regular follow-up, reviewing pacing percentage, capture, atrial arrhythmia burden, and paced QRS morphology.
- Repeat echocardiography when symptoms develop, pacing burden rises, or at a planned interval in patients expected to pace frequently.
- Investigate a fall in LVEF for ischemia, tachycardia, valve disease, renal or volume changes, and medication-related causes before assigning blame to pacing alone.
- Refer promptly for electrophysiology review when high-burden right ventricular pacing coincides with ventricular dilation, worsening strain, or reduced LVEF.
Pacing-induced ventricular dysfunction is a preventable or reversible form of heart failure in many patients, provided it is recognized early. Consistent device surveillance, comparative cardiac imaging, physiological pacing choices, and timely CRT or conduction-system pacing can protect ventricular performance and improve symptoms. Clinicians can deepen that approach by reviewing current electrophysiology research, clinical guidance, and device outcomes in the Journal of Arrhythmia, then applying the evidence to individualized pacing follow-up and timely referral.